| Literature DB >> 35287732 |
Margarita-Ioanna Koufaki1, Stavroula Siamoglou1, George P Patrinos1,2,3, Konstantinos Vasileiou4.
Abstract
BACKGROUND: There is an increasing interest worldwide in investigating healthcare stakeholders' perceptions and intentions to adopt pharmacogenomics (PGx) into clinical practice. However, the existing inquiries based on well-established theories and models that interpret their intentions to implement PGx are scarce. This study is the first that examines the impact of selected factors on health science students' intention to adopt genetic testing applications using the technology acceptance model while it compares two different cultural groups: Greeks (Europe; Christian) and Malays (Asia; Muslim).Entities:
Keywords: Comparative analysis; Different cultural settings; Genetic testing; Genomics; Health science students; Intentions to adopt; Path analysis; Perceptions; Questionnaire survey
Mesh:
Year: 2022 PMID: 35287732 PMCID: PMC8919586 DOI: 10.1186/s40246-022-00382-3
Source DB: PubMed Journal: Hum Genomics ISSN: 1473-9542 Impact factor: 4.639
Fig. 1Theoretical model of students’ intention to adopt genetic testing and its predicting factors
Sample descriptive statistics (valid %)
| Variables | Greece ( | Malaysia ( | ||
|---|---|---|---|---|
| % | % | |||
| Male | 75 | 36.6 | 55 | 27.4 |
| Female | 130 | 63.4 | 146 | 72.6 |
| 1 | 172 | 83.9 | 1 | 0.5 |
| 2 | 32 | 15.6 | 107 | 53.2 |
| 3 | 0 | 0 | 78 | 38.8 |
| 4 | 1 | 0.5 | 11 | 5.5 |
| 5 | 0 | 0 | 4 | 2.0 |
| Pharmacy | 77 | 37.6 | 82 | 40.8 |
| Medicine | 128 | 62.4 | 119 | 59.2 |
Results of exploratory factor analysis
| Factors and variables | Greece ( | Malaysia ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Factor loadings (56.65%) | Factor loadings (65.85%) | |||||||||
| Fac. 1 | Fac. 2 | Fac. 3 | Fac. 4 | Fac. 5 | Fact. 1 | Fac. 2 | Fac. 3 | Fac. 4 | Fac. 5 | |
| Draw a pedigree | 0.841 | 0.871 | ||||||||
| Discuss with a family the results of a genetic test and consult | 0.847 | 0.861 | ||||||||
| Diagnosis | 0.720 | 0.779 | ||||||||
| Treatments | 0.696 | 0.813 | ||||||||
| Prevention | 0.693 | 0.723 | ||||||||
| Prognosis | 0.587 | 0.716 | ||||||||
| Drug efficacy increase | 0.627 | 0.694 | ||||||||
| Medication cost reduction | 0.711 | 0.755 | ||||||||
| Incidence of adverse drug reactions reduction | 0.786 | 0.854 | ||||||||
| Severity of adverse drug reactions reduction | 0.765 | 0.849 | ||||||||
| Exacerbation reduction | 0.623 | 0.784 | ||||||||
| Privacy and confidentiality not protected | 0.657 | 0.645 | ||||||||
| Promotes discrimination against groups of people | 0.759 | 0.697 | ||||||||
| Leads to unforeseen consequences | 0.697 | 0.682 | ||||||||
| Affects my employability | 0.765 | 0.818 | ||||||||
| Renders me unable to get insured | 0.724 | 0.760 | ||||||||
| Can be misused by corporate or government bodies | 0.749 | 0.735 | ||||||||
| Will help people to live better lives | 0.748 | 0.686 | ||||||||
| Valuable for early detection of diseases | 0.625 | 0.746 | ||||||||
| Will help people to live longer and better | 0.739 | 0.741 | ||||||||
| Can help a child to live a better life | 0.653 | 0.726 | ||||||||
| % of explained variance | 17.551 | 15.439 | 9.438 | 7.853 | 6.366 | 31.584 | 11.637 | 9.747 | 7.036 | 5.850 |
| Initial Eigenvalues | 3.686 | 3.242 | 1.982 | 1.649 | 1.337 | 6.633 | 2.444 | 2.047 | 1.478 | 1.228 |
| Cronbach alpha | 0.821 | 0.759 | 0.688 | 0.676 | 0.701 | 0.890 | 0.835 | 0.790 | 0.764 | 0.734 |
| Item-scale correlations | 0.519–0.638 | 0.445–0.610 | 0.394–0.585 | 0.422–0.491 | 0.542 | 0.645–0814 | 0.488–0.717 | 0.525–0.603 | 0.526–0.594 | 0.581 |
| CR | 0.87 | 0.83 | 0.79 | 0.77 | 0.83 | 0.89 | 0.87 | 0.84 | 0.82 | 0.86 |
| AVE | 0.53 | 0.50 | 0.48 | 0.46 | 0.71 | 0.62 | 0.53 | 0.58 | 0.53 | 0.75 |
Comparison of students’ views on questionnaire items
| Factors and variables | Greece ( | Malaysia ( | Mann–Whitney test | |||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Z | Asymp. sig. (2-tailed) | |
| Draw a pedigree | 3.35 | 1.30 | 3.27 | 0.99 | − 1.280 | 0.201 |
| Discuss with a family the results of a genetic test and consult | 2.56 | 1.20 | 3.13 | 1.05 | − 4.939 | 0.000 |
| Diagnosis | 4.35 | 0.92 | 4.09 | 0.72 | − 4.697 | 0.000 |
| Treatments | 4.13 | 0.95 | 4.07 | 0.76 | − 1.695 | 0.090 |
| Prevention | 4.26 | 0.89 | 4.10 | 0.77 | − 2.718 | 0.007 |
| Prognosis | 4.25 | 0.90 | 4.09 | 0.80 | − 2.713 | 0.007 |
| Drug efficacy increase | 3.77 | 0.99 | 3.95 | 0.75 | − 1.520 | 0.129 |
| Medication cost reduction | 3.20 | 1.03 | 3.73 | 0.89 | − 5.495 | 0.000 |
| Incidence of adverse drug reactions reduction | 3.55 | 0.95 | 3.89 | 0.76 | − 3.580 | 0.000 |
| Severity of adverse drug reactions reduction | 3.53 | 0.92 | 3.82 | 0.83 | − 2.943 | 0.003 |
| Exacerbation reduction | 3.37 | 0.97 | 3.70 | 0.83 | − 3.213 | 0.001 |
| Privacy and confidentiality not protected | 2.72 | 1.17 | 3.40 | 1.02 | − 5.922 | 0.000 |
| Promotes discrimination against groups of people | 2.89 | 1.27 | 3.58 | 0.94 | − 5.561 | 0.000 |
| Leads to unforeseen consequences | 3.56 | 1.11 | 3.66 | 0.90 | − 0.410 | 0.682 |
| Affects my employability | 3.62 | 1.16 | 3.69 | 0.90 | − 0.194 | 0.846 |
| Renders me unable to get insured | 3.36 | 1.18 | 3.70 | 0.88 | − 2.706 | 0.007 |
| Can be misused by corporate or government bodies | 3.78 | 0.99 | 3.78 | 0.91 | − 0.540 | 0.589 |
| Will help people to live better lives | 4.54 | 0.66 | 4.28 | 0.78 | − 3.562 | 0.000 |
| Valuable for early detection of diseases | 4.61 | 0.76 | 4.31 | 0.81 | − 4.840 | 0.000 |
| Will help people to live longer and better | 4.35 | 0.81 | 4.01 | 0.87 | − 4.208 | 0.000 |
| Can help a child to live a better life | 4.18 | 0.94 | 4.05 | 0.78 | − 2.423 | 0.015 |
| To know my own genetic profile | 4.18 | 1.03 | 4.31 | 0.93 | − 1.039 | 0.299 |
| To know my potential future diseases | 4.07 | 1.12 | 4.20 | 0.93 | − 0.622 | 0.534 |
Fig. 2Path diagram of Greek sample (standardized estimates)
Fig. 3Path diagram of Malaysian sample (standardized estimates)
Model fitness indices for both SEM models
| Index | Greece | Malaysia | Accepted value(s)* |
|---|---|---|---|
| CMIN/DF | 0.568 | 0.331 | 2.0–5.0 |
| 0.892 | 0.987 | ≥ 0.05 | |
| IFI | 1.033 | 1.055 | ≥ 0.95 |
| NFI | 0.96 | 0.975 | ≥ 0.95 |
| TLI | 1.051 | 1.094 | ≥ 0.95 |
| CFI | 1.000 | 1.000 | ≥ 0.95 |
| RMSEA | 0.000 | 0.000 | ≤ 0.08 |
| PCLOSE | 0.986 | 0.999 | ≥ 0.05 |
*Sources Hooper et al. [27], Schreiber et al.[28]